BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 3338271)

  • 1. Structure of C3f, a small peptide specifically released during inactivation of the third component of complement.
    Harrison RA; Farries TC; Northrop FD; Lachmann PJ; Davis AE
    Complement; 1988; 5(1):27-32. PubMed ID: 3338271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g.
    Davis AE; Harrison RA; Lachmann PJ
    J Immunol; 1984 Apr; 132(4):1960-6. PubMed ID: 6607952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor C3f is a spasmogenic fragment released from C3b by factors I and H: the heptadeca-peptide C3f was synthesized and characterized.
    Ganu VS; Müller-Eberhard HJ; Hugli TE
    Mol Immunol; 1989 Oct; 26(10):939-48. PubMed ID: 2531841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of C3 in C3 glomerulopathy.
    Sethi S; Vrana JA; Fervenza FC; Theis JD; Sethi A; Kurtin PJ; Zhang Y; Smith RJH
    Nephrol Dial Transplant; 2017 Mar; 32(3):459-465. PubMed ID: 27507892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis.
    Klickstein LB; Bartow TJ; Miletic V; Rabson LD; Smith JA; Fearon DT
    J Exp Med; 1988 Nov; 168(5):1699-717. PubMed ID: 2972794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The difference between human C3F and C3S results from a single amino acid change from an asparagine to an aspartate residue at position 1216 on the alpha-chain of the complement component, C3.
    Poznansky MC; Clissold PM; Lachmann PJ
    J Immunol; 1989 Aug; 143(4):1254-8. PubMed ID: 2473125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural characterization of factor I mediated cleavage of the third component of complement.
    Davis AE; Harrison RA
    Biochemistry; 1982 Nov; 21(23):5745-9. PubMed ID: 6217832
    [No Abstract]   [Full Text] [Related]  

  • 8. Studies on the structure of complement C3 and the stability of C3 derived phagocytic ligands C3b/iC3b in SJL/J and BALB/c mice.
    Lynch DM; Kay PH; Papadimitriou JM; Grounds MD
    Eur J Immunogenet; 1993 Feb; 20(1):1-9. PubMed ID: 8443150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bovine conglutinin binds to an oligosaccharide determinant presented by iC3b, but not by C3, C3b or C3c.
    Laursen SB; Thiel S; Teisner B; Holmskov U; Wang Y; Sim RB; Jensenius JC
    Immunology; 1994 Apr; 81(4):648-54. PubMed ID: 7518801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products.
    Farries TC; Lachmann PJ; Harrison RA
    Biochem J; 1988 May; 252(1):47-54. PubMed ID: 3421908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation of residues in the C3dg region of human complement component C3 corresponding to a proposed binding site for complement receptor type 2 (CR2, CD21) does not abolish binding of iC3b or C3dg to CR2.
    Diefenbach RJ; Isenman DE
    J Immunol; 1995 Mar; 154(5):2303-20. PubMed ID: 7868901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
    Sahu A; Kay BK; Lambris JD
    J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formation of covalently linked C3-C3 dimers on IgG immune aggregates.
    Barrio E; Antón LC; Marqués G; Sánchez A; Vivanco F
    Eur J Immunol; 1991 Feb; 21(2):343-9. PubMed ID: 1999223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Component C3 of hagfish complement has a unique structure: identification of native C3 and its degradation products.
    Fujii T; Nakamura T; Tomonaga S
    Mol Immunol; 1995 Jun; 32(9):633-42. PubMed ID: 7643855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deposition of C3b and iC3b onto particulate activators of the human complement system. Quantitation with monoclonal antibodies to human C3.
    Newman SL; Mikus LK
    J Exp Med; 1985 Jun; 161(6):1414-31. PubMed ID: 2409200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The attachment of serum- and plasma-derived C3 to solid-phase immune aggregates and its relation to complement-mediated solubilization of immune complexes.
    Baatrup G; Svehag SE; Jensenius JC
    Scand J Immunol; 1986 Apr; 23(4):397-406. PubMed ID: 3486458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Purification and characterization of bovine complement component C3 and its cleavage products.
    Di Carlo AL; Paape MJ; Hellman J; Lilius EM
    Am J Vet Res; 1997 Jun; 58(6):585-9. PubMed ID: 9185962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C3 binds with similar efficiency to Fab and Fc regions of IgG immune aggregates.
    Antón LC; Ruiz S; Barrio E; Marqués G; Sánchez A; Vivanco F
    Eur J Immunol; 1994 Mar; 24(3):599-604. PubMed ID: 8125130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distribution of activated complement, C3b, and its degraded fragments, iC3b/C3dg, in the colonic mucosa of ulcerative colitis (UC).
    Ueki T; Mizuno M; Uesu T; Kiso T; Nasu J; Inaba T; Kihara Y; Matsuoka Y; Okada H; Fujita T; Tsuji T
    Clin Exp Immunol; 1996 May; 104(2):286-92. PubMed ID: 8625522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preimplantation embryos cooperate with oviductal cells to produce embryotrophic inactivated complement-3b.
    Tse PK; Lee YL; Chow WN; Luk JM; Lee KF; Yeung WS
    Endocrinology; 2008 Mar; 149(3):1268-76. PubMed ID: 18039777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.